Table 3.
Unadjusted and Adjusted Odds Ratios Comparing Numbers of Human Papillomavirus Vaccine Doses Received in CIN2+ Cases With and Without Human Papillomavirus Type 16/18 Among Vaccinated Women With CIN2+, HPV-IMPACT, United States, 2008–2014
| No. of HPV Vaccine Doses Given ≥24 Months Before Screening | OR | 95% CI | Adjusted ORa | 95% CI |
|---|---|---|---|---|
| Versus 1 dose | ||||
| 1 | 1.00 | Referent | 1.00 | Referent |
| 2 | 0.91 | 0.53, 1.55 | 0.96 | 0.55, 1.68 |
| 3 | 0.55 | 0.35, 0.85 | 0.61 | 0.38, 0.99 |
| Versus 2 doses | ||||
| 2 | 1.00 | Referent | 1.00 | Referent |
| 3 | 0.60 | 0.37, 0.98 | 0.64 | 0.39, 1.05 |
Abbreviations: CI, confidence interval; CIN, cervical intraepithelial neoplasia; CIN2+, CIN grade 2, 2/3, or 3 and adenocarcinoma in situ; HPV, human papillomavirus; HPV-IMPACT, Human Papillomavirus Vaccine Impact Monitoring Project; OR, odds ratio.
a
Adjusted for surveillance site, race/ethnicity, health insurance status, and age at vaccination.